Author:
Blackwell K.,Gascon P.,Jones C.M.,Nixon A.,Krendyukov A.,Nakov R.,Li Y.,Harbeck N.
Reference28 articles.
1. Key considerations in the preclinical development of biosimilars;Bui;Drug Discov Today,2015
2. Totality of the evidence at work: the first U.S. biosimilar;Holzmann;Expert Opin Biol Ther,2016
3. Biosimilars versus original biologics. Similarities and differences from development to approval;Windisch;Z Rheumatol,2015
4. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies—Non-clinical and Clinical Issues;European Medicines Agency,2014
5. Federal Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. April 2015; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf (1 July 2016, date last accessed).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献